Neogen Stock Rallies 83% YTD: What's Driving the Surge?

Neogen shares have rallied 83% year-to-date, supported by fiscal Q4 2026 Food Safety revenue growth of 3.1% and core growth of 5.8%, its strongest quarterly rate since fiscal 2023. Indicator Testing and Culture Media revenue rose 9.5%, while Bacterial and General Sanitation grew 9.9%; Neogen is also bringing Petrifilm manufacturing in-house and plans to increase fiscal 2027 R&D spending by about 50%. Offsetting factors include consensus expectations for fiscal 2027 EPS to decline 3.1% to $0.31 and revenue to rise only 1.5% to $883.2 million, alongside competitive and FX risks. The company also agreed in March 2026 to sell its Genomics business to Zoetis for $160 million, pending approvals.

Analysis

NEOG’s rerating now requires an earnings bridge, not another narrative upgrade. A modest organic-growth inflection is encouraging, but the forward setup embeds a difficult tradeoff: materially higher innovation spend and manufacturing transition costs arrive before any meaningful revenue acceleration is visible in consensus. The key 1-3 month catalyst is whether management can demonstrate gross-margin expansion from internalized production while holding selling costs flat; absent that, the stock’s sharp momentum makes it vulnerable to a guidance reset despite improving product mix.

The Genomics divestiture to ZTS is strategically cleaner but removes a recurring data-enabled revenue stream and creates a comparability issue for FY28 estimates. The $160m proceeds can improve leverage and fund Food Safety investment, yet the market should demand evidence that reinvestment returns exceed the lost contribution. ZTS gains a modest adjacency in livestock selection, but the financial impact is unlikely to move its estimates; the more relevant read-through is whether ZTS subsequently acquires additional animal-health diagnostics assets.

Contrarian view: in-house Petrifilm production is not automatically margin-accretive. Early utilization, validation, yield and inventory build can temporarily dilute gross margin, while incumbents such as Bio-Rad and Thermo Fisher can defend strategic food-testing accounts through bundled instruments and reagents. NEOG’s thesis is falsified if Food Safety core growth retreats below mid-single digits, FY27 operating-margin guidance fails to expand, or the divestiture closing is delayed; with earnings still expected to decline, these risks matter more than incremental product-launch announcements.

Key Decisions for Investors

• Do not chase NEOG after the momentum move; place on a 1-3 month watchlist for the next earnings call. Initiate only if management quantifies FY27 gross-margin expansion and Food Safety core growth sustains at or above 5%; otherwise the risk is a valuation de-rating on lower EPS.
• For existing NEOG longs, retain a reduced tactical position but hedge with a 3-6 month put spread around the next results date. Take profits if management raises R&D without offsetting operating-margin or free-cash-flow guidance.
• Use ZTS as the cleaner large-cap expression of animal-health consolidation rather than as a direct read-through trade on the acquired business. Reassess only after transaction close and disclosure of acquired revenue, retention, and integration costs.
• Monitor a relative-value setup: long PAHC versus short NEOG only if NEOG’s forward valuation premium widens further without an upward FY27 EPS revision. PAHC offers more current earnings yield, while NEOG requires execution on margin recovery; close the spread if NEOG provides credible margin guidance or PAHC misses animal-health demand expectations.